Regeneron-backed oncolytic virus startup scores modest Series B extension

Three years ago, Regeneron collaborated with tiny, Rochester, MN biotech Vyriad to kickstart a Phase II trial. That collaboration deal would combine Regeneron’s PD-1 drug Libtayo with the biotech’s Voyager-V1 program, an oncolytic virus derived from the Vesicular stomatitis virus.

The trial was looking at multiple types of cancer such…